Company Information & Drug Savings for Alnylam Pharmaceuticals Medications
Alnylam Pharmaceuticals is a leading biopharmaceutical company pioneering RNA interference (RNAi) therapeutics. Based in Cambridge, Massachusetts, Alnylam develops treatments for rare genetic diseases, cardio-metabolic diseases, and hepatic infectious diseases. FDA-approved products include Onpattro (patisiran) and Amvuttra (vutrisiran) for hereditary transthyretin-mediated amyloidosis, Givlaari (givosiran) for acute hepatic porphyria, and Oxlumo (lumasiran) for primary hyperoxaluria type 1. Alnylam’s innovative platform harnesses natural RNAi pathways to silence disease-causing genes.
How to Contact Alnylam Pharmaceuticals
Phone
1-617-551-8200Medical Disclaimer
NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current. However, the knowledge and experience of a qualified healthcare professional should always be sought after instead of using the information on this page. Before taking any drug, you should always speak to your doctor or another qualified healthcare provider.
The information provided here about medications is subject to change and is not meant to include all uses, precautions, warnings, directions, drug interactions, allergic reactions, or negative effects. The absence of warnings or other information for a particular medication does not imply that the medication or medication combination is appropriate for all patients or for all possible purposes.
Experienced a Side Effect?
Report to Yellow Card (UK) or MedWatch (US)
